No Data
No Data
Jiudian Pharmaceutical's H1 Profit Jumps 44% as Revenue Climbs 12%
Hunan Jiudian Pharmaceutical: Summary of Half-Year Report in 2024.
Hunan Jiudian Pharmaceutical: Half-year report for the year 2024.
Hunan Jiudian Pharmaceutical (300705.SZ) supervisor Duan Bin and Liang Shenghua plan to reduce their holdings by a total of no more than 0.1937 million shares.
Hunan Jiudian Pharmaceutical (stock code: 300705.SZ) announced that its supervisors Duan Bin and Liang Shenghua plan to reduce their shareholdings in the company, with a total of...
Jiudian Pharma Gets China Nod to Market Ambroxol Hydrochloride Oral Solution
Hunan Jiudian Pharmaceutical (300705.SZ) has obtained the drug registration certificate for the oral solution of ambroxol hydrochloride.
Hunan Jiudian Pharmaceutical (300705.SZ) announced on August 13 that the company has recently received the Drug Registration Certificate issued by the National Medical Products Administration for oral solution of ambroxol hydrochloride. The ambroxol hydrochloride oral solution can increase the secretion of mucous glands in the respiratory mucosa and reduce mucus gland secretion, thereby reducing the viscosity of phlegm. It also promotes the secretion of lung surfactant and increases the ciliary movement of the bronchi to make phlegm easy to cough up, which is suitable for the viscosity of phlegm caused by acute and chronic bronchitis and difficult expectoration.
No Data